In Vivo Activities of Farnesyl Pyrophosphate Synthase Inhibitors against Leishmania donovani and Toxoplasma gondii-Reference-Cited by-同舟云学术

In Vivo Activities of Farnesyl Pyrophosphate Synthase Inhibitors against Leishmania donovani and Toxoplasma gondii

Published:2002-03 Issue:3 Volume:46 Page:929-931
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Yardley Vanessa¹,Khan Anis A.²,Martin Michael B.³,Slifer Teri R.²,Araujo Fausto G.²,Moreno Silvia N. J.⁴,Docampo Roberto⁴,Croft Simon L.¹,Oldfield Eric³⁵

Affiliation:

1. Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom

2. Department of Infectious Diseases, Palo Alto Medical Foundation, Palo Alto, California 94301

3. Department of Chemistry

4. Laboratory of Molecular Parasitology, Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802

5. Department of Biophysics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801

Abstract

ABSTRACT The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii . Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani- infected mice but was less effective against T. gondii -infected mice.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.3.929-931.2002

Reference6 articles.

1. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection

2. Croft, S. L., D. Snowdon, and V. Yardley. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani,Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother.38:1041-1047.

3. Ezra, A., A. Hoffman, E. Breuer, I. S. Alferiev, J. Monkkonen, N. El Hanany-Rozen, G. Weiss, D. Stepenksy, I. Gati, H. Cohen, S. Tormalehto, G. L. Amidon, and G. Golomb. 2000. A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem.43:3641-3652.

4. Martin, M. B., J. S. Grimley, J. C. Lewis, H. T. Heath III, B. N. Bailey, H. Kendrick, V. Yardley, A. Caldera, R. Lira, J. A. Urbina, S. N. J. Moreno, R. Docampo, S. L. Croft, and E. Oldfield. 2001. Bisphosphonates inhibit the growth of Trypanosoma brucei,Trypanosoma cruzi,Leishmania donovani,Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem.44:909-916.

5. Montalvetti, A., B. N. Bailey, M. B. Martin, G. W. Severin, E. Oldfield, and R. Docampo. 2001. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem.276:33930-33937.

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation and characterization of paromomycin encapsulated in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis;Current Analytical Chemistry;2024-07-29

2. An updated review of chemical compounds with anti-Toxoplasma gondii activity;European Journal of Medicinal Chemistry;2023-12

3. Design, Synthesis, Antimicrobial Evaluation, and Molecular Docking Studies of Carbamoyl Phosphonates;Russian Journal of Organic Chemistry;2023-12

4. Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development;International Immunopharmacology;2023-02

5. The Heptaprenyl Diphosphate Synthase (Coq1) Is the Target of a Lipophilic Bisphosphonate That Protects Mice against Toxoplasma gondii Infection;mBio;2022-10-26